[Surgical sepsis. II. Effectiveness of immune therapy with recombinant interleukin-2].
Two methods of administration of Roncoleukin were used as two subcutaneous injections in dose of 500,000 units with a 3 day interval and in the regimen of extracorporeal immunotherapy. The use of Roncoleukin resulted in the clinical improvement in 83% of patients and in the detoxicating and immunocorrecting effects in 77.3 and 60% respectively which was reliably different from analogous indices (33.4%, 45% and 7.5%) in the placebo group. Other values of the prognosed lethality being equal, the real 28-day lethality in the placebo group was 21.5%, while the using of Roncoleukin allowed the level of lethality of patients with surgical sepsis to become 3.8 times lower, including the subgroup of patients with severe sepsis from 50 to 13.6%. The trials performed showed the drug Roncoleukin to be endurable and not toxic and allowed to determine the indications and contraindications to using cytokin therapy in the complex treatment of pyo-septic diseases.
Ostanin
A A
AA
Zaĭnutdinov
Iu G
IuG
Strel'tsova
E I
EI
Ovechkin
A V
AV
Ageev
N L
NL
Leplina
O Iu
OIu
Tikhonova
M A
MA
Chernykh
E R
ER
D018806:APACHE; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002478:Cells, Cultured; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011183:Postoperative Complications / Q000188:drug therapy* / Q000401:mortality; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000401:mortality; D013997:Time Factors
D007376:Interleukin-2; D010919:Placebos